Home > For Consumers > Relaxin for preventing preterm birth for...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD010073.pub2

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Relaxin for preventing preterm birth for women in preterm labour

This version published: 2013; Review content assessed as up-to-date: July 05, 2013.

Link to full article: [Cochrane Library]

Plain language summary

Preterm labour (contractions of the uterus and changes in the cervix before 37 completed weeks of pregnancy) can lead to preterm (early) birth of the baby. Preterm birth is a leading cause of illness and death for newborn babies. Tocolytic agents are used to prevent uterine contractions and can help to delay birth. Relaxin is a hormone that is produced by the ovary and placenta with important effects in the female reproductive system and during pregnancy. This review aimed to assess whether relaxin given to mothers in preterm labour could delay or prevent preterm birth.

We included three small randomised trials involving 149 women in preterm labour in the review. These trials were conducted in the 1950s and had a high risk of bias overall. We found no convincing evidence that relaxin (given by intravenous and intramuscular injection) can prevent preterm birth for women in preterm labour. Only one of the studies, involving 30 women (and at a high risk of bias), reported on birth within seven days of treatment and found that women who received relaxin were less likely to give birth preterm within seven days of treatment, and were more likely to have a longer pregnancy than women who did not receive relaxin. The risk of babies dying was not significantly different between the women who received relaxin and those who did not. Neither of the other two trials found clear differences in preterm birth, and no trial reported on longer‐term outcomes for the babies. There is therefore insufficient evidence from this review to recommend relaxin as an intervention to prevent preterm birth for women in preterm labour.

Abstract

Background: Preterm birth is a leading cause of perinatal morbidity and mortality. Early animal and clinical studies have provided some evidence to support an inhibitory effect of relaxin on preterm birth for women in preterm labour.

Objectives: To assess the effects of relaxin for women in preterm labour on preterm birth and associated maternal and neonatal/infant health outcomes.

Search methods: We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (30 June 2013), and the reference lists of relevant papers.

Selection criteria: Randomised and quasi‐randomised controlled trials assessing the effects of relaxin compared with no treatment, a placebo, or an alternative tocolytic, for preventing preterm birth for women in preterm labour. Primary review outcomes included birth within 28 hours of treatment, birth within seven days of treatment, perinatal mortality, and a serious neonatal adverse outcome composite.

Data collection and analysis: Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of included studies.

Main results: We included three quasi‐randomised controlled trials, with a total of 149 women and their babies. All three trials were at a high risk of bias. When comparing women receiving relaxin with those who did not receive relaxin, there was a significant reduction in birth within seven days of treatment in one trial of 30 women (risk ratio (RR) 0.50, 95% confidence interval (CI) 0.29 to 0.87), yet no significant difference was seen for perinatal mortality in this trial (RR 0.83, 95% CI 0.32 to 2.15). The second and third included trials did not report on any of the primary outcomes pre‐specified in the review, including birth within 48 hours of treatment, birth within seven days of treatment, perinatal mortality, and serious neonatal adverse outcomes.

One trial found a significant increase in pregnancy prolongation for women receiving relaxin (RR 8.00, 95% CI 1.14 to 56.33; 30 women). None of the three included trials found significant differences in the outcomes of fetal death, neonatal death, birthweight or preterm birth, and no trial reported on longer‐term outcomes for the babies.

Authors' conclusions: There is limited randomised controlled trial evidence available on the effect of relaxin during pregnancy for preventing preterm birth for women in preterm labour. Evidence from one quasi‐randomised trial suggested a reduction in birth within seven days of treatment for women receiving relaxin, compared with women in a control group, however this trial was at a high risk of bias and included only 30 women. There is thus insufficient evidence to support or refute the use of relaxin in women in preterm labour for preventing preterm birth.

Editorial Group: Cochrane Pregnancy and Childbirth Group.

Publication status: New.

Citation: Bain E, Heatley E, Hsu K, Crowther CA. Relaxin for preventing preterm birth. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010073. DOI: 10.1002/14651858.CD010073.pub2. Link to Cochrane Library. [PubMed: 23949874]

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 23949874

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...